[Clinical analysis of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction in 24 cases].

Objective: To observe the therapeutic effect of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction (AMI).

Method: The clinic data of 24 patients treated with early stage thrombolytic therapy with venous urokinase and 18 conventional therapy were reviewed, and the repatency of the coronary artery and T-wave inversion within 24 h after the treatment were evaluated.

Result: The repatency rate of urokinase group and conventional therapy group was 62.5% and 15.0%, respectively, showing significant difference (P<0.05). Shorter delay of administration of thrombolytic therapy after infarction onset resulted in higher rate of repatency.

Conclusion: Early stage thrombolytic therapy with venous urokinase can improve the therapeutic effect and reduce the mortality rate of AMI, and is therefore recommended for clinical application.